Active substanceFluconazoleFluconazole
Similar drugsTo uncover
  • Vero-Fluconazole
    capsules inwards 
    VEROPHARM SA     Russia
  • Disorel-Sanovel
    capsules inwards 
  • Diflazon®
    solution d / infusion 
  • Diflucan®
    powder inwards 
    Pfizer Inc.     USA
  • Diflucan®
    capsules inwards 
    Pfizer Inc.     USA
  • Diflucan®
    solution in / in 
    Pfizer Inc.     USA
  • Micon
    solution d / infusion 
  • Medoflucon®
    capsules inwards 
    MEDSERV, LLC     Russia
  • Mycomomax®
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Mycosyst®
    capsules inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Mycosyst®
    solution d / infusion 
    GEDEON RICHTER, OJSC     Hungary
  • Mycoflucan®
    pills inwards 
  • Mycoflucan®
    solution d / infusion 
  • Nofung®
    capsules inwards 
  • Procanazole
    capsules inwards 
  • Fangifflu
    capsules inwards 
  • Flukozan
    solution d / infusion 
    LENS-PHARM, LLC     Russia
  • Flukoside
    capsules inwards 
  • Flukomabol®
    solution d / infusion 
    PREBAND PFC, LLC     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    PHARMACY 36.6, CJSC     Russia
  • Fluconazole
    solution d / infusion 
  • Fluconazole
    capsules inwards 
  • Fluconazole
    solution d / infusion 
    RUSYUROFARM, LLC     Russia
  • Fluconazole
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Fluconazole
    capsules inwards 
    REPLEK FARM Skopje, OOO     Macedonia
  • Fluconazole
    capsules inwards 
    FARMPROJECT, CJSC     Russia
  • Fluconazole
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    OZONE, LLC     Russia
  • Fluconazole
    capsules inwards 
    BIOKOM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    VERTEKS, AO     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    pills inwards 
    TECHNOLOG, JSC     Ukraine
  • Fluconazole
    capsules inwards 
    Hemofarm AD     Serbia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    Astrafarm, CJSC     Russia
  • Fluconazole
    capsules inwards 
    MEDISORB, CJSC     Russia
  • Fluconazole OBL
    capsules inwards 
  • Fluconazole Zentiva
    solution d / infusion 
    Zentiva c.s.     Czech Republic
  • Fluconazole Cabi
    solution d / infusion 
  • Fluconazole STADA
    capsules inwards 
  • Fluconazole-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
  • Fluconazole-Sandoz®
    capsules inwards 
    Sandoz d.     Slovenia
  • Fluconazole-Teva
    capsules inwards 
  • Flukonorm
    capsules inwards 
  • Flucorus®
    solution d / infusion 
    MS-VITA, LLC     Russia
  • Flukorem
    gel externally 
    REMEDIYA, LLC     Russia
  • Flucostat®
    solution d / infusion 
  • Flucostat®
    capsules inwards 
  • Forkan®
    solution d / infusion 
    Cipla Ltd.     India
  • Forkan®
    capsules inwards 
    Cipla Ltd.     India
  • Ciscan®
    capsules inwards 
  • Dosage form: & nbspsolution for infusions
    Composition:

    Active substance: 100 ml of the solution contains 200 mg of fluconazole.

    Excipients: sodium chloride - 900,00 mg, water for injection - up to 100,00 ml.

    Description:A colorless or slightly colored transparent solution.
    Pharmacotherapeutic group:Antifungal agent
    ATX: & nbsp

    J.02.A.C   Triazole derivatives

    J.02.A.C.01   Fluconazole

    Pharmacodynamics:

    Fluconazole is a representative of the class of triazole derivatives, it is a selective inhibitor of the synthesis of sterols in the fungal cell. Blocking the conversion of lanosterol of fungal cells to ergosterol; increases the permeability of the cell membrane.

    Fluconazole, being highly selective for cytochrome P450 fungi, practically does not inhibit the cytochrome P450 system in the human body (in comparison with itraconazole, clotrimazole, econazole and ketoconazole less inhibits oxidative processes dependent on cytochrome P450 in human liver microsomes). Does not have androgenic activity.

    The drug is active in mycoses caused by Candida spp., Cryptococcus neoformans, Microsporum spp., Trichophyton spp., Blastomyces dermatidis, Coccidioides immitis and Histoplasma capsulatum.

    Pharmacokinetics:

    After intravenous administration fluconazole well penetrates into tissues and body fluids. Concentrations of the drug in saliva, sputum, breast milk, articular and peritoneal fluid are similar to its concentration in blood plasma. In patients with fungal meningitis, the fluconazole content in the cerebrospinal fluid reaches 80% of the corresponding plasma concentration.

    Concentrations in the plasma are in a direct proportion to the dose. 90% equilibrium concentration is reached by 4-5 days with daily administration once a day.

    The application on the first day of a dose, twice the usual daily dose, allows reaching 90% of the equilibrium concentration by the second day. The apparent volume of distribution approximates the total volume of water in the body. 11-12% of fluconazole binds to plasma proteins. The half-life (T1/2) - 30 hours. The pharmacokinetics of fluconazole significantly depends on the functional state of the kidneys, and there is an inverse relationship between T1/2 and CC (creatinine clearance). Fluconazole is excreted from the body, mainly by the kidneys; while approximately 80% of the administered dose is excreted unchanged. The clearance of fluconazole is directly proportional to the creatinine clearance. After hemodialysis for 3 hours, the concentration of fluconazole in the plasma is reduced by 50%. Metabolites in the peripheral blood were not detected.

    Indications:
    • Cryptococcosis: cryptococcal meningitis, cryptococcal infections of the lungs and skin; cryptococcal sepsis; prevention of recurrence of cryptococcosis in AIDS patients, organ transplantation or other cases of immunodeficiency.
    • Generalized candidiasis: candidemia, disseminated candidiasis and other forms of invasive candidiasis infections (infections of the abdominal cavity, endocardium, eyes, respiratory and urinary tracts), including in patients receiving a course of cytostatic or immunosuppressive therapy, and in the presence of other factors predisposing to development of candidiasis - treatment and prevention.
    • Candidiasis of the mucous membranes: the oral cavity, including atrophic candidiasis of the oral cavity, associated with the wearing of dentures, pharynx, esophagus and non-invasive bronchopulmonary infections, candiduria.
    • Genital candidiasis: vaginal (acute or in chronic recurrent form).
    • Prevention of fungal infections in patients with malignant neoplasms that are predisposed to such infections as a result of chemotherapy with cytostatics or radiation therapy; prevention of recurrence of oropharyngeal candidiasis in AIDS patients.
    • Mycosis of the skin, trunk, inguinal region;
    • Deep endemic mycoses, including coccidioidosis, paracoccidioidosis and histoplasmosis in patients with normal immunity.
    Contraindications:
    • Hypersensitivity to the drug or similar in structure to azole compounds.
    • Simultaneous use of terfenadine (against the background of the continuous use of fluconazole at a dose of 400 mg per day and above) and cisapride, as both drugs prolong the QT interval and increase the risk of severe cardiac rhythm disturbances.
    • Simultaneous use of astemizole.
    • Lactation period.
    Carefully:

    Hepatic and / or renal insufficiency, the appearance of rash against the background of fluconazole in patients with superficial fungal infection and invasive / systemic fungal infections, simultaneous administration of fluconazole with rifabutin or other drugs metabolized by the cytochrome P450 system, concurrent administration of terfenadine and fluconazole at a dose of less than 400 mg per day, potentially proaritmogenic states in patients with multiple risk factors (organic heart disease, electrolyte balance disorders, at the same time ny receiving drugs that cause arrhythmias); patients with intolerance to acetylsalicylic acid, pregnancy.

    Pregnancy and lactation:

    The use of fluconazole during pregnancy is possible only if the potential benefit to the mother exceeds the risk to the fetus.

    Fluconazole is defined in breast milk in the same concentration as in plasma, so its use during lactation is contraindicated.

    Dosing and Administration:

    Enter intravenously drip at a rate of not more than 20 mg (10 ml) per minute.

    When transferring from intravenous administration to taking capsules and vice versa, there is no need to change the daily dose.

    The infusion solution is compatible with the following solutions: 20% glucose solution, Ringer's solution, Hartman's solution, potassium chloride solution in glucose, sodium bicarbonate solution, 0.9% sodium chloride solution.

    Infusions of fluconazole can be carried out using conventional transfusion kits using one of the liquids listed above.

    Application in adults

    In cryptococcal infections, the usual dose of fluconazole is 400 mg once a day on the first day of treatment, later on - 200-400 mg once a day. The duration of treatment for cryptococcal infections depends on the clinical efficacy, confirmed by mycological examination, and usually ranges from 6 to 8 weeks.

    The recommended duration of treatment for cryptococcal meningitis is 10-12 weeks after a negative result of a microbiological study of a sample of cerebrospinal fluid.

    To prevent the recurrence of cryptococcal meningitis in AIDS patients after completing the full course of primary therapy fluconazole appoint a patient in a dose of at least 200 mg per day for a long period.

    With candidemia, disseminated candidiasis and other invasive candidiasis infections, the daily dose of fluconazole is 400 mg on the first day and 200 mg on subsequent days. If necessary, the dose of the drug can be increased to 400 mg / day. The duration of treatment depends on clinical effectiveness.

    With severe systemic candidiasis - it is possible to increase the dose to 800 mg per day. The duration of therapy depends on clinical effectiveness. Should continue at least 2 weeks after receiving negative blood cultures or after the disappearance of the symptoms of the disease.

    In oropharyngeal candidiasis, including patients with impaired immunity, the usual dose of fluconazole is 50-100 mg once a day for 7-14 days. To prevent the recurrence of oropharyngeal candidiasis in AIDS patients after completing the full course of primary therapy - 150 mg once a week. If necessary, the treatment can be prolonged, especially with severe immunity disorders.

    With atrophic candidiasis of the oral cavity, associated with the wearing of dentures, fluconazole usually appoint 50 mg once a day for 14 days in combination with antiseptic agents to handle the prosthesis.

    In other candidiasis infections, for example, with esophagitis, noninvasive bronchopulmonary infections, candiduria, candidiasis of the skin and mucous membranes, the daily dose is 50-100 mg for 14-30 days.

    In severe candidiasis of the mucous membranes - 100-200 mg per day.

    For the prevention of fungal infections in patients with malignant neoplasms, the dose of fluconazole should be 50 mg once a day until the patient is at a high risk because of cytotoxic or radiation therapy.

    With vaginal candidiasis - 150 mg once. To reduce the frequency of relapses, once a month, 150 mg are used for 4-12 months, sometimes more frequent use may be required.

    For the prevention of candidiasis, the recommended dose of fluconazole is 50-400 mg once a day, depending on the degree of risk of fungal infection. If there is a high risk of generalized infection, for example, in patients with expected severe or persistent neutropenia, the recommended dose is 400 mg once daily. Fluconazole appoint a few days before the expected appearance of neutropenia; after increasing the number of neutrophils more than 1000 / mm3 treatment is continued for another 7 days.

    With deep endemic mycoses, it may be necessary to use the drug at a dose of 200-400 mg per day for 2 years. The duration of therapy is determined individually; it can be 11-24 months with coccidioidosis; 2-17 months with paracoccidioidosis and 3-17 months with histoplasmosis.

    Use in children

    The duration of treatment depends on the clinical and mycological effect. In children, the drug should not be used in a daily dose exceeding that of adults.

    In candidiasis of mucous membranes, the recommended dose of fluconazole is 3 mg / kg per day. On the first day, a shock dose of 6 mg / kg can be given to achieve a more rapid equilibrium concentration.

    For the treatment of generalized candidiasis and cryptococcal infection, the recommended dose is 6-12 mg / kg per day, depending on the severity of the disease.

    For the prevention of fungal infections in children with reduced immunity, in which the risk of developing infection is associated with neutropenia,developing as a result of cytotoxic chemotherapy or radiotherapy, the drug is prescribed at 3-12 mg / kg per day, depending on the severity and duration of preservation of induced neutropenia.

    In newborns fluconazole is slower, so in the first 2 weeks of life the drug is prescribed in the same dose (in mg / kg) as in older children, but at an interval of 72 hours. Children aged 3-4 weeks of life are given the same dose at intervals of 48 hours.

    Application in elderly patients

    In the absence of violations of the kidneys should follow the usual recommendations for dosing the drug. For patients with impaired renal function (creatinine clearance <50 mL / min), the dosage regimen should be adjusted as indicated below.

    Use in patients with renal insufficiency

    Fluconazole is excreted mainly by the kidneys in unchanged form. With a single application of fluconazole, no dose changes are required. If a course of treatment is necessary in patients (including children) with impaired renal function, a "shock" dose of 50 mg to 400 mg should be initially administered. In the future, the daily dose (depending on the indication) is determined according to the following table:

    Creatinine clearance (ml / min)

    % of recommended dose

    >50

    100%, once a day

    <50 (without dialysis)

    50%, once a day

    Patients on continuous dialysis

    100%, after each dialysis session

    Side effects:

    From the digestive system: nausea, vomiting, diarrhea, flatulence, abdominal pain, taste change, liver function disorder (hyperbilirubinemia, increased activity of "liver" transaminases, alkaline phosphatase, jaundice, hepatitis, hepatocellular necrosis, including fatal).

    From the nervous system: headache, dizziness, convulsions.

    On the part of the organs of hematopoiesis: leukopenia, thrombocytopenia, neutropenia, agranulocytosis.

    Allergic reactions: skin rash, multiforme exudative erythema (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), anaphylactoid reactions (including angioedema, facial edema, urticaria, skin itching), bronchial asthma (more often with intolerance to acetylsalicylic acid).

    From the side of the cardiovascular system: increase in the duration of the QT interval on an electrocardiogram, fibrillation / flutter of the ventricles.

    Other: a violation of kidney function, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

    Overdose:

    Symptoms: nausea, vomiting, diarrhea, in severe cases, convulsions, hallucinations, paranoid behavior may occur.

    Treatment: symptomatic (gastric lavage, forced diuresis, hemodialysis). After a three-hour hemodialysis session, the concentration of fluconazole in the blood plasma is reduced by approximately 50%.

    Interaction:

    Anticoagulants: In patients receiving fluconazole and indirect anticoagulants of the coumarin series, careful monitoring of prothrombin time is necessary, since it may increase.

    Preparations of sulfonylureas: fluconazole with the simultaneous administration may extend the half-life of sulfonylurea derivatives, therefore, when combined, the possibility of developing hypoglycemia should be considered.

    Phenytoin: the simultaneous use of fluconazole and phenytoin may be accompanied by an increase in the concentration of phenytoin in a clinically significant degree, which requires a reduction in its dose.

    Rifampicin: with simultaneous administration of rifampicin and fluconazole, the maximum concentration and half-life of the latter decrease, therefore, if a combined use is necessary, the dose of fluconazole should be increased.

    Rifabutin: the combined use of fluconazole and rifabutin is accompanied by an increase in serum concentration of the latter, possibly the development of uveitis.

    Cyclosporin: with the combined use of fluconazole and cyclosporine, it is recommended to monitor the concentration of the latter in the blood, since it can increase.

    Terfenadine: taking into account the occurrence of serious, life-threatening arrhythmias in patients taking antifungal agents - azole derivatives in combination with terfenadine, their joint administration is contraindicated.

    Cisapride: with simultaneous administration of fluconazole and cisapride, cases of unwanted reactions from the heart, including paroxysms of ventricular tachycardia, have been described. Simultaneous reception is contraindicated.

    Zidovudine: when combined with fluconazole, zidovudine concentration in the blood plasma may increase. Patients taking this combination should be observed to identify side effects of zidovudine.

    Theophylline: the use of fluconazole leads to a decrease in the average clearance rate of theophylline from the blood plasma, therefore, the risk of toxic theophylline and its overdose increases.

    Midazolam: simultaneous application of fluconazole and midazolam leads to a significant increase in the concentration of the latter in blood plasma and the risk of developing psychomotor reactions.

    Hydrochlorothiazide: with the simultaneous administration of fluconazole and hydrochlorothiazide, the concentration of fluconazole in the blood plasma increases by 40%.

    Tacrolimus: with the simultaneous administration of fluconazole and tacrolimus, the concentration of the latter in the serum increases, which leads to an increased risk of nephrotoxicity.

    Care should be taken when using fluconazole in patients who are simultaneously receiving other drugs metabolized by the cytochrome P450 system.

    Special instructions:

    Treatment with fluconazole must be continued until the appearance of clinical hematological remission. Premature termination of treatment leads to relapse.

    Because the fluconazole is excreted mainly by the kidneys, caution should be exercised in patients with renal insufficiency. With long-term treatment with fluconazole, dosing should be carried out taking into account the clearance of creatinine.

    In rare cases, the use of fluconazole was accompanied by a toxic effect on the liver, including fatalities,mainly in patients with serious concomitant diseases. It is necessary to monitor liver function. If there are signs of liver damage that may be associated with the use of fluconazole, the drug should be discontinued.

    Against the background of taking the drug in patients, there were rare cases of development of exfoliative skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Patients with AIDS and malignant neoplasms are more likely to develop severe skin reactions with many drugs. If the patient develops a superficial fungal infection of the rash during treatment, which can be associated with the use of fluconazole, the drug should be discontinued. When rashes appear in patients with invasive / systemic fungal infections, they should be carefully monitored and canceled fluconazole with the appearance of bullous lesions or erythema multiforme.

    Caution should be exercised while taking fluconazole with rifabutin or other drugs metabolized by the cytochrome P450 system.

    It is necessary to monitor prothrombin time in patients simultaneously receiving fluconazole and indirect anticoagulants of the coumarin series.

    Effect on the ability to drive transp. cf. and fur:
    Patients should be careful when driving vehicles or when working with machinery, since dizziness may occur during fluconazole treatment.
    Form release / dosage:
    Solution for infusion, 2 mg / ml.
    Packaging:

    100 ml of a solution for infusions in a glass bottle (1 hydrolytic class) with a plug of gray bromobutyl rubber with a combined flip-off cap made of Al-Fe-Si alloy and green polypropylene.

    One bottle, one plastic holder for droppers and one instruction for use in a cardboard bundle.

    Storage conditions:

    At a temperature of no higher than 30 ° C.

    Keep out of the reach of children!

    Shelf life:

    2 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N012167 / 02
    Date of registration:02.06.2010 / 03.02.2012
    Expiration Date:Unlimited
    The owner of the registration certificate:GEDEON RICHTER, OJSC GEDEON RICHTER, OJSC Hungary
    Manufacturer: & nbsp
    Information update date: & nbsp07.06.2018
    Illustrated instructions
      Instructions
      Up